CP and aceruloplasminemia: On a different note, productivity would need to be greatly increased and, more importantly, the finding that HexNAc2Hex8 and HexNAc2Hex11 glycan chains are predominant in recombinant CP indicates that the glycan structure is probably unsuitable and further careful glycoengineering of the SM5 strain will be mandatory before any potential therapeutic use of the recombinant protein for enzyme replacement therapy of aceruloplasminemia patients can be envisaged.